Associated Papers
Human iPSC-based breast cancer model identifies S100P-dependent cancer stemness induced by BRCA1 mutation.
Liu J et al.
Science Advances, 2025
The UGT1A9*22 genotype identifies a high-risk group for irinotecan toxicity among gastric cancer patients.
Lee CK et al.
Genomics & Informatics, 2022
Prioritization of candidate genes for a South African family with Parkinson's disease using in-silico tools.
Sebate B et al.
Plos One, 2021
UGT1A3 and Sex Are Major Determinants of Telmisartan Pharmacokinetics-A Comprehensive Pharmacogenomic Study.
Hirvensalo P et al.
Clinical Pharmacology and Therapeutics, 2020
UGT1A1*6, UGT1A7*3 and UGT1A9*1b polymorphisms are predictive markers for severe toxicity in patients with metastatic gastrointestinal cancer treated with irinotecan-based regimens.
Cui C et al.
Oncology Letters, 2016
Somatic signature of brain-specific single nucleotide variations in sporadic Alzheimer's disease.
Parcerisas A et al.
Journal of Alzheimer's Disease : Jad, 2014
Differences in frequencies of UGT1A9, 1A7, and 1A1 genetic polymorphisms in Chinese Tibetan versus Han Chinese populations.
Yan W et al.
Genetics and Molecular Research : Gmr, 2013
S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis.
Kim SY et al.
British Journal of Cancer, 2013
Pharmacogenetic study of deferasirox, an iron chelating agent.
Lee JW et al.
Plos One, 2013
Genetic variants and haplotypes of the UGT1A9, 1A7 and 1A1 genes in Chinese Han.
Zhang X et al.
Genetics and Molecular Biology, 2012
Polymorphisms in heterocyclic aromatic amines metabolism-related genes are associated with colorectal adenoma risk.
Eichholzer M et al.
International Journal of Molecular Epidemiology and Genetics, 2012
Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer.
Wong NS et al.
Pharmacogenetics and Genomics, 2011
Part 3: Pharmacogenetic variability in phase II anticancer drug metabolism.
Deenen MJ et al.
The Oncologist, 2011
Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.
Ramírez J et al.
Future Oncology (london, England), 2010
Close association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or *60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese.
Saito Y et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2009
Family 1 uridine-5'-diphosphate glucuronosyltransferases (UGT1A): from Gilbert's syndrome to genetic organization and variability.
Strassburg CP et al.
Archives of Toxicology, 2008
Update on tools for evaluation of uridine diphosphoglucuronosyltransferase polymorphisms.
Argikar UA et al.
Expert Opinion on Drug Metabolism & Toxicology, 2008
UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity.
Biason P et al.
Journal of Chemotherapy (florence, Italy), 2008
Genetic variations and haplotypes of UDP-glucuronosyltransferase 1A locus in a Korean population.
Yea SS et al.
Therapeutic Drug Monitoring, 2008
Linkage disequilibrium of UGT1A1 *6 and UGT1A1 *28 in relation to UGT1A6 and UGT1A7 polymorphisms.
Urawa N et al.
Oncology Reports, 2006
Crohn's disease in Japanese is associated with a SNP-haplotype of N-acetyltransferase 2 gene.
Machida H et al.
World Journal of Gastroenterology, 2005
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Carlini LE et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2005
Genetic polymorphisms of the UDP-glucuronosyltransferase 1A7 gene and irinotecan toxicity in Japanese cancer patients.
Ando M et al.
Japanese Journal of Cancer Research : Gann, 2002
Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.
Ando Y et al.
Cancer Research, 2000
Fire Usage and Ancient Hominin Detoxification Genes: Protective Ancestral Variants Dominate While Additional Derived Risk Variants Appear in Modern Humans.
Aarts JM et al.
Plos One, 0